What is PrEPVacc?
PrEPVacc is an African-led, European-supported HIV prevention study running in East and Southern Africa from 2018 to 2024.
For the first time, it is combining evaluation of experimental HIV vaccines and pre-exposure prophylaxis (PrEP) at the same time.
In December 2023, the study announced that it had stopped further vaccinations as there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition.
In July 2024, PrEPVacc reported the results of the HIV vaccine trial, which show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population.
The results of the oral PrEP study will be announced later in 2024.
